GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.80
Bid: 40.50
Ask: 40.90
Change: 3.65 (9.83%)
Spread: 0.40 (0.988%)
Open: 37.95
High: 40.80
Low: 37.95
Prev. Close: 37.15
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

John Clarke to Chair Futura

1 Nov 2011 07:00

RNS Number : 2026R
Futura Medical PLC
01 November 2011
 



For immediate release

1 November 2011

 

 

 

Futura Medical plc

("Futura" or "the Company")

 

Appointment of Non-Executive Chairman

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is delighted to announce the appointment of John Clarke, the highly experienced GlaxoSmithKline ("GSK") executive, as Non-Executive Chairman.

Mr Clarke has extensive experience of the healthcare sector, having worked at GSK for more than 35 years. In 2006 he was appointed President of GSK Consumer Healthcare, a position from which he recently stepped down. Under Mr Clarke's leadership, GSK Consumer Healthcare became one of the fastest-growing companies in its industry. It achieved 60% sales growth between 2006 and 2010, when it recorded a turnover of £5 billion.

Mr Clarke's appointment at Futura will be effective on 1 February 2012.

Mr Clarke will replace Dr William Potter, who will step down from the Board on 1 February 2012 but continue to play a key role as Futura's Chief Scientific Officer. David Davies, Futura's Product Development Director, becomes Chief Development Director, reflecting the Company's increasing emphasis on its product pipeline.

John Clarke, Futura's Chairman Designate, commented: "I am delighted to be taking on the Chairmanship of Futura. I am particularly impressed by the level of innovation at Futura, by the commercial potential of its late stage products and by the breadth of its product pipeline. I look forward to assisting the Company in achieving its true potential."

James Barder, Futura's Chief Executive, said: "John Clarke is recognised as an outstanding leader in the consumer healthcare industry and we are therefore delighted that he has decided to join Futura at this exciting stage in our development. I would like to give my profound thanks to Bill Potter for his tenure as Chairman, and am delighted that he will be remaining with the Company as Chief Scientific Officer."

 

 

Additional information:

 

John Milne Clarke, age 62 years, holds no shares in Futura. He was President of GlaxoSmithKline Worldwide Consumer Healthcare. He is a member of GlaxoSmithKline plc Corporate Executive Team and a director of the US-based Consumer Healthcare Products Association.

 

There are no further disclosures to be made in relation to Mr Clarke under Schedule 2(g) and (i) of the AIM rules.

 

 

 

For any further information please contact:

 

Futura Medical plc

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

mail to: james.barder@futuramedical.com

www.futuramedical.com

Nomura Code Securities Limited

Phil Walker / Giles Balleny

Tel:+44 (0)20 7776 1200

For media enquiries please contact:

Buchanan

Mark Court / Jessica Fontaine

Tel: +44 (0) 20 7466 5000

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDFLFXFBFFFBK
Date   Source Headline
25th Jun 20212:55 pmRNSTR1: Notification of Major Holdings
15th Jun 20213:48 pmRNSTR-1: Notification of major holdings
9th Jun 20213:58 pmRNSTR-1: Notification of major holdings
3rd Jun 20214:19 pmRNSTR-1: Notification of major holdings
3rd Jun 202111:00 amRNSNotice of AGM and Annual Report
2nd Jun 202112:50 pmRNSResult of General Meeting & Total Voting Rights
1st Jun 20217:00 amRNSBlock Listing Six Monthly Return
17th May 20213:08 pmRNSPosting of Circular and Notice of General Meeting
17th May 20217:00 amRNSResult of Placing and Retail Offer
14th May 20214:41 pmRNSSecond Price Monitoring Extn
14th May 20214:35 pmRNSPrice Monitoring Extension
14th May 20214:31 pmRNSRetail Offer by PrimaryBid
14th May 20214:30 pmRNSProposed Placing to raise £10 mil & Retail Offer
4th May 20215:18 pmRNSTR-1: Notification of major holdings
4th May 20215:15 pmRNSTR-1: Notification of major holdings
4th May 20217:00 amRNSTotal Voting Rights
30th Apr 20217:00 amRNSFutura Receives Approval from EU Notified Body
28th Apr 20212:57 pmRNSTR-1: Notification of major holdings
28th Apr 20219:31 amRNSTR-1: Notification of major holdings
22nd Apr 20214:58 pmRNSTR-1: Notification of major holdings
19th Apr 20214:03 pmRNSCorrection – Conversion of Convertible Loan Notes
15th Apr 20212:42 pmRNSConversion of Convertible Loan Notes
14th Apr 20213:40 pmRNSRemuneration of Non-Executive Directors and TVR
14th Apr 20217:00 amRNSFull Year Results for the year ended 31 Dec 2020
1st Apr 20214:20 pmRNSExercise of Warrants, Issue of Equity & TVR
30th Mar 20212:18 pmRNSNotice of Results
25th Mar 20214:41 pmRNSSecond Price Monitoring Extn
25th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 202111:05 amRNSSecond Price Monitoring Extn
24th Mar 202111:00 amRNSPrice Monitoring Extension
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:41 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:36 pmRNSPrice Monitoring Extension
23rd Mar 20212:05 pmRNSSecond Price Monitoring Extn
23rd Mar 20212:01 pmRNSPrice Monitoring Extension
23rd Mar 20219:05 amRNSSecond Price Monitoring Extn
23rd Mar 20219:00 amRNSPrice Monitoring Extension
22nd Mar 20217:00 amRNSUS FDA Agreement for Confirmatory Clinical study
19th Mar 20214:41 pmRNSSecond Price Monitoring Extn
19th Mar 20214:36 pmRNSPrice Monitoring Extension
19th Mar 202111:06 amRNSSecond Price Monitoring Extn
19th Mar 202111:00 amRNSPrice Monitoring Extension
19th Mar 20217:00 amRNSFutura Receives Recommendation for Approval
4th Mar 20212:05 pmRNSSecond Price Monitoring Extn
4th Mar 20212:00 pmRNSPrice Monitoring Extension
4th Mar 20219:06 amRNSSecond Price Monitoring Extn
4th Mar 20219:00 amRNSPrice Monitoring Extension
4th Mar 20217:00 amRNSFutura Announces Investment & Joint Collaboration
25th Feb 20212:06 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.